share_log

Cantor Fitzgerald Initiates Coverage On Legend Biotech With Overweight Rating, Announces Price Target of $82

Cantor Fitzgerald Initiates Coverage On Legend Biotech With Overweight Rating, Announces Price Target of $82

坎托·菲茨杰拉德以增持评级启动对Legend Biotech的报道,宣布目标股价为82美元
Benzinga ·  04/03 07:47

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Target of $82.

坎托·菲茨杰拉德分析师里克·比恩科夫斯基以增持评级启动了对传奇生物科技(纳斯达克股票代码:LEGN)的报道,并宣布目标股价为82美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发